Phase I study to determine Safety and Pharmacokinetics of subcutaneous administration of potent and broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed and uninfected (HEU) neonates and infants (PedMAb1)
PedMAb1 is being conducted as a partnership between the SAMRC, IRCCS Ospedale San Raffaele, Milan, Italy, University of Montpellier, France, Wits Health Consortium and University of Bergen, Norway, with funding from EDCTP and the SAMRC
Read More